Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
239.00
-1.08 (-0.45%)
At close: Aug 26, 2026, 4:00 PM EDT
238.18
-0.82 (-0.34%)
After-hours: Aug 26, 2026, 7:47 PM EDT

Alnylam Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,7081,657966.43812.69866.39819.98
Short-Term Investments
1,6001,2511,7281,6271,3261,616
Cash & Short-Term Investments
3,3082,9082,6952,4392,1922,436
Cash Growth
15.77%7.94%10.46%11.27%-9.98%29.94%
Accounts Receivable
912.74777.57405.31327.79237.96198.57
Receivables
912.74777.57405.31327.79237.96198.57
Inventory
97.1182.7278.5189.15128.9686.36
Prepaid Expenses
302.18281.89116.96126.38132.9288.08
Total Current Assets
4,6204,0513,2952,9832,6922,809
Property, Plant & Equipment
737.5708.06693.93725.79738.63733.63
Long-Term Deferred Tax Assets
113.79125.98116.8610.1--
Other Long-Term Assets
87.381.63133.9111.29115.48101.1
Total Assets
5,5594,9664,2403,8303,5463,643

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
108.02115.7288.4255.5298.0973.43
Accrued Expenses
1,096821.34701.38654.73513.78372.33
Current Portion of Long-Term Debt
258.57220.07113.0254.9940.2937.08
Current Portion of Leases
45.9345.5241.8941.5141.9740.55
Current Unearned Revenue
4.014.8555.48102.7542.11149.48
Other Current Liabilities
-258.86186.0958.2831.6822.84
Total Current Liabilities
1,5131,4661,186967.79767.92695.71
Long-Term Debt
2,4722,4782,3592,3432,2691,827
Long-Term Leases
210.5225.09229.54243.1261.34281.35
Long-Term Unearned Revenue
---188.18193.79152.36
Other Long-Term Liabilities
9.157.59398.11308.44212.5898.96
Total Liabilities
4,2054,1774,1734,0513,7053,055

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1.341.321.291.261.241.2
Additional Paid-In Capital
7,7177,5107,3886,8116,4556,058
Retained Earnings
-6,332-6,703-7,288-7,010-6,569-5,438
Comprehensive Income & Other
-32.14-20.1-34.52-23.38-44.65-33.26
Shareholders' Equity
1,354789.1867.09-220.64-158.22588.2
Total Liabilities & Equity
5,5594,9664,2403,8303,5463,643

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,9872,9692,7432,6832,6132,186
Net Cash (Debt)
320.66-60.31-48.92-243.24-420.15249.87
Net Cash Growth
172.09%-----11.29%
Net Cash Per Share
2.31-0.45-0.38-1.95-3.452.11
Filing Date Shares Outstanding
133.81132.62129.46125.95124.13120.21
Total Common Shares Outstanding
133.73132.38129.29125.79123.93120.18
Working Capital
3,1082,5842,1092,0151,9242,113
Book Value Per Share
10.135.960.52-1.75-1.284.89
Tangible Book Value
1,354789.1867.09-220.64-158.22588.2
Tangible Book Value Per Share
10.135.960.52-1.75-1.284.89
Land
-9.089.089.089.089.08
Buildings
-297.62294.51271.65269.32262.64
Machinery
-247.12225.2202.89173.1137.86
Construction In Progress
-40.957.6730.114.680.75
Leasehold Improvements
-241.08236.69235.41230.85152.05
SEC Filings: 10-K · 10-Q